Wire · opportunities
FDA Approves Zanidatamab Regimen for HER2-Positive GEA
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
The FDA has approved zanidatamab with or without tislelizumab combined with chemotherapy as a first-line treatment for HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. This approval includes companion diagnostic tests to identify eligible patients and is based on trial results showing improved overall and progression-free survival compared to the previous standard trastuzumab regimen.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 25 Aug 2026 and 26 Aug 2026.
◆ ◆ The Wire takeaway
You can now target HER2-positive gastric and related cancers with zanidatamab combinations immediately, opening new treatment options and diagnostics markets beyond trastuzumab. Her2 cancer therapy innovators face a fresh competitive benchmark to beat in immunotherapy and diagnostics.
◆ Coverage
8 sources · first reported 25 Aug 2026 · latest 26 Aug 2026
◆ Topics